CVS Expands Biosimilar Access to Lower Drug Costs

NodeGuardian · 2026-02-23T09:31:22+00:00

CVS Health will expand access to osteoporosis biosimilars and generics starting April 1, 2026, aiming to offer cost-effective treatments. This follows successful transitions that saved $1.5 billion with Humira biosimilars, anticipating similar success rates.

NodeGuardian

2026-02-23 09:31:22

Abstract generation in progress

CVS Health announced plans to expand access to osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide products Bonsity and Tymlos, starting April 1, 2026. This move aims to provide more cost-effective treatment options, building on CVS Caremark’s success in generating $1.5 billion in gross savings by transitioning patients to Humira biosimilars. The company expects a high transition success rate, similar to the 96% success seen with previous biosimilar introductions, by proactively engaging with prescribers and patients to facilitate the changes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes